



Message from the SPORT study Chief Investigator

Welcome to the second SPORT participant newsletter. Since our first newsletter which many of you have told us you found very useful, a number of things have happened and you will find information about these developments in this newsletter.

Our big news is that we have now achieved our target recruitment - 850 of you have kindly signed up to the study across 13 hospitals. This is a tremendous achievement and we are very grateful to each and every one of you for your time and commitment to research.

Overall, the study is going extremely well and the numbers on the right give some idea of the scale of the project. Recently Cancer Research UK, who fund the project, have given us a time extension recognising that participant recruitment in the early stages was delayed due to the pandemic. In order to gather as much information as possible and make the study even more valuable to researchers we have asked the Research Ethics Committee if we can make some changes to how it is run. Further information about these changes is in this issue.

I do hope that you find this update useful and once again, from the entire SPORT team, many thanks for your contributions.

Professor
Robert Rintoul



SPORT Study reaches 850 participants

We are delighted to announce that we have recruited 850 participants from 13 hospitals across the United Kingdom to our study, achieving our recruitment target. Thank you so much for being part of it! The next step of our study is to keep asking you to provide a blood sample and data every six months. Your blood samples are being carefully processed in our laboratory in Cambridge and are being used to develop new scientific approaches for early detection of lung cancer.



SPORT study in numbers




13 hospitals involved



850 participants



3085 visits



58 litres of blood donated



Second phase will allow data follow-up



Due to the success of the study to date, we have recently been allowed by the Research Ethics Committee to update our Patient Information Sheet and Informed Consent Form (PIS/ICF) as well as ask your permission to follow your cancer journey records for a further 5 years. We would track your journey using data from the NHS Cancer Registries, once your face-to-face visits end. Your local team will give you more details about this second phase of the study at your next visit.

Meet the Trial Management Group

Along with our local teams, the Trial Management Group oversees the running of the study, ensuring that all aspects are in line with the approved protocols and that the study remains current and viable. In the photo, from left to right: Raitza Vieira (Research and Development Administrative Assistant), Hannah Thomas (Research Assistant), Professor Nitzan Rosenfeld (Group Leader), Professor Robert Rintoul (Chief Investigator), Ellen Moseley (Trial Manager), Sarah Fielding (Research and Development Manager). The Lead Scientist, Sarah Jensen (not shown in the photo), is also a member of our team but is currently on leave.



You said, we did

Q: How long will I be in the study?

A: Patients who joined the study before February 2021 will have face-to-face visit for 5 years. Patients who joined after February 2021 will end their time in face-to-face study around February 2026.

Q: When will the study results be shared with the patients?

A: The results will be available at the end of the study, after we have collected, tested, and analysed all the samples. However, we are already looking at the data we have compiled so far. We will publish a scientific paper in 2025 with an overview of our recruited study group. We will keep you updated in the next issue of this newsletter.